Cell-death-associated molecular patterns as determinants of cancer immunogenicity

Antioxidants and Redox Signaling

Volumn 20, Issue 7, 2014, Pages 1098-1116

  Ladoire, Sylvain ^a,b,c   Hannani, Dalil ^a,b,d   Vetizou, Marie ^a,b,d   Locher, Clara ^a,b,d   Aymeric, Laetitia ^a,b,d   Apetoh, Lionel ^a,c,e   Kepp, Oliver ^a,b,d   Kroemer, Guido ^a,b,f,g,h   Ghiringhelli, François ^a,c,e   Zitvogel, Laurence ^a,b,d,i  

^a INSERM   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c CENTRE GEORGES FRANÇOIS LECLERC   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e UNIVERSITÉ DE BOURGOGNE   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g CENTRE DE RECHERCHE DES CORDELIERS   (France)

^h HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

ⁱ Center of Clinical Investigations in Biotherapies of Cancer (CICBT)   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; CELL DEATH; CYTOKINES; HMGB1 PROTEIN; HUMANS; NEOPLASMS;

EID: 84894085241     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2012.5133     Document Type: Review

References (171)

1. Ahrens S, Zelenay S, Sancho D, Hanc P, Kjaer S, Feest C, Fletcher G, Durkin C, Postigo A, Skehel M, Batista F, Thompson B, Way M, Reise Sousa C, and Schulz O. F-Actin is an evolutionarily conserved damage-Associated molecular pattern recognized by DNGR-1, a receptor for dead cells. Immunity 36: 635-645, 2012.
2. Ait-Tahar K, Barnardo MC, and Pulford K. CD4 T-helper responses to the anaplastic lymphoma kinase (ALK) protein in patients with ALK-positive anaplastic large-cell lymphoma. Cancer Res 67: 1898-1901, 2007.
3. Ait-Tahar K, Cerundolo V, Banham AH, Hatton C, Blanchard T, Kusec R, Becker M, Smith GL, and Pulford K. B and CTL responses to the ALK protein in patients with ALK-positive ALCL. Int J Cancer 118: 688-695, 2006.
4. Albert ML, Sauter B, and Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class Irestricted CTLs. Nature 392: 86-89, 1998.
5. Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, Mariette C, Chaput N, Mira JP, Delaloge S, Andre F, Tursz T, Kroemer G, and Zitvogel L. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 220: 47-59, 2007.
6. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, Andre F, Delaloge S, Tursz T, Kroemer G, and Zitvogel L. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13: 1050-1059, 2007.
7. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, Frees K, Watt JL, and Schwartz DA. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 25: 187-191, 2000.
8. Aychek T, Miller K, Sagi-Assif O, Levy-Nissenbaum O, Israeli-Amit M, Pasmanik-Chor M, Jacob-Hirsch J, Amariglio N, Rechavi G, and Witz IP. E-selectin regulates gene expression in metastatic colorectal carcinoma cells and enhances HMGB1 release. Int J Cancer 123: 1741-1750, 2008.
9. Bartling B, Hofmann HS, Weigle B, Silber RE, and Simm A. Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis 26: 293-301, 2005.
10. Bastid J, Cottalorda-Regairaz A, Alberici G, Bonnefoy N, Eliaou JF, and Bensussan A. ENTPD1/CD39 is a promising therapeutic target in oncology. Oncogene 2012. [Epub ahead of print]; DOI: 10.1038/onc.2012.269.
11. Bell CW, Jiang W, Reich CF, 3rd, and Pisetsky DS. The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 291: C1318-C1325, 2006.
12. Beneteau M, Zunino B, Jacquin MA, Meynet O, Chiche J, Pradelli LA, Marchetti S, Cornille A, Carles M, and Ricci JE. Combination of glycolysis inhibition with chemotherapy results in an antitumor immune response. Proc Natl Acad Sci U S A 109: 20071-20076, 2012.
13. Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A, Rubartelli A, Agresti A, and Bianchi ME. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 22: 5551-5560, 2003.
14. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, and Wigginton JM. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455-2465, 2012.
15. Bunt SK, Yang L, Sinha P, Clements VK, Leips J, and Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloidderived suppressor cells and limits tumor progression. Cancer Res 67: 10019-10026, 2007.
16. Canbolat O, Durak I, Cetin R, Kavutcu M, Demirci S, and Ozturk S. Activities of adenosine deaminase, 5¢-nucleotidase, guanase, and cytidine deaminase enzymes in cancerous and non-cancerous human breast tissues. Breast Cancer Res Treat 37: 189-193, 1996.
17. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, Schmitt E, Hamai A, Hervas-Stubbs S, Obeid M, Coutant F, Metivier D, Pichard E, Aucouturier P, Pierron G, Garrido C, Zitvogel L, and Kroemer G. Caspasedependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 202: 1691-1701, 2005.
18. Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, Weiskopf K, Willingham SB, Raveh T, Park CY, Majeti R, and Weissman IL. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2: 63ra94, 2010.
19. Chavakis E, Hain A, Vinci M, Carmona G, Bianchi ME, Vajkoczy P, Zeiher AM, Chavakis T, and Dimmeler S. Highmobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circ Res 100: 204-212, 2007.
20. Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, Fujioka Y, Ohba Y, Gorman JV, Colgan JD, Hirashima M, Uede T, Takaoka A, Yagita H, and Jinushi M. Tumor-infiltrating DCs suppress nucleic acidmediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol 13: 832-842, 2012.
21. Choi JJ, Reich CF, 3rd, and Pisetsky DS. Release of DNA from dead and dying lymphocyte and monocyte cell lines in vitro. Scand J Immunol 60: 159-166, 2004.
22. Choi YR, Kim H, Kang HJ, Kim NG, Kim JJ, Park KS, Paik YK, and Kim HO. Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation. Cancer Res 63: 2188-2193, 2003.
23. Das D, Peterson RC, and Scovell WM. High mobility group B proteins facilitate strong estrogen receptor binding to classical and half-site estrogen response elements and relax binding selectivity. Mol Endocrinol 18: 2616-2632, 2004.
24. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirstrom K, West BL, and Coussens LM. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1: 54-67, 2011.
25. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, von Torne C, Weichert W, Engels K, Solbach C, Schrader I, Dietel M, and von Minckwitz G. Tumor-Associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28: 105-113, 2010.
26. Di Virgilio F. Liaisons dangereuses: P2X(7) and the inflammasome. Trends Pharmacol Sci 28: 465-472, 2007.
27. Disis ML. Immune regulation of cancer. J Clin Oncol 28: 4531-4538, 2010.
28. This reference has been deleted.
29. Ditsworth D, Zong WX, and Thompson CB. Activation of poly(ADP)-ribose polymerase (PARP-1) induces release of the pro-inflammatory mediator HMGB1 from the nucleus. J Biol Chem 282: 17845-17854, 2007.
30. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 60: 540-551, 2003.
31. Dong Xda E, Ito N, Lotze MT, Demarco RA, Popovic P, Shand SH, Watkins S, Winikoff S, Brown CK, Bartlett DL, and Zeh HJ, 3rd. High mobility group box I (HMGB1) release from tumor cells after treatment: Implications for development of targeted chemoimmunotherapy. J Immunother 30: 596-606, 2007.
32. Dumitriu IE, Baruah P, Valentinis B, Voll RE, Herrmann M, Nawroth PP, Arnold B, Bianchi ME, Manfredi AA, and Rovere-Querini P. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 174: 7506-7515, 2005.
33. Dumitriu IE, Bianchi ME, Bacci M, Manfredi AA, and Rovere-Querini P. The secretion of HMGB1 is required for the migration of maturing dendritic cells. J Leukoc Biol 81: 84-91, 2007.
34. Durak H, Ertay T, Sayit E, Aktogu S, Kut O, Guven H, and Gure A. Lung clearance of aerosolized 99mTc erythromycin lactobionate in rabbits. Nucl Med Biol 23: 291-293, 1996.
35. Elaraj DM, Weinreich DM, Varghese S, Puhlmann M, Hewitt SM, Carroll NM, Feldman ED, Turner EM, and Alexander HR. The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clin Cancer Res 12: 1088-1096, 2006.
36. Ellerman JE, Brown CK, De Vera M, Zeh HJ, Billiar T, Rubartelli A, and Lotze MT. Masquerader: High mobility group box-1 and cancer. Clin Cancer Res 13: 2836-2848, 2007.
37. Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, Park D, Woodson RI, Ostankovich M, Sharma P, Lysiak JJ, Harden TK, Leitinger N, and Ravichandran KS. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461: 282-286, 2009.
38. Eroglu A, Canbolat O, Demirci S, Kocaoglu H, Eryavuz Y, and Akgul H. Activities of adenosine deaminase and 5'-nucleotidase in cancerous and noncancerous human colorectal tissues. Med Oncol 17: 319-324, 2000.
39. Fages C, Nolo R, Huttunen HJ, Eskelinen E, and Rauvala H. Regulation of cell migration by amphoterin. J Cell Sci 113 (Pt 4): 611-620, 2000.
40. Ferrari D, Pizzirani C, Adinolfi E, Lemoli RM, Curti A, Idzko M, Panther E, and Di Virgilio F. The P2X7 receptor: A key player in IL-1 processing and release. J Immunol 176: 3877-3883, 2006.
41. Finn OJ. Cancer immunology. N Engl J Med 358: 2704-2715, 2008.
42. Flohr AM, Rogalla P, Meiboom M, Borrmann L, Krohn M, Thode-Halle B, and Bullerdiek J. Variation of HMGB1 expression in breast cancer. Anticancer Res 21: 3881-3885, 2001.
43. Formenti SC and Demaria S. Effects of chemoradiation on tumor-host interactions: The immunologic side. J Clin Oncol 26: 1562-1563; author reply 1563, 2008.
44. Fritz JH, Ferrero RL, Philpott DJ, and Girardin SE. Nod-like proteins in immunity, inflammation and disease. Nat Immunol 7: 1250-1257, 2006.
45. Fucikova J, Kralikova P, Fialova A, Brtnicky T, Rob L, Bartunkova J, and Spisek R. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res 71: 4821-4833, 2011.
46. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, and Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964, 2006.
47. Gardai SJ, Bratton DL, Ogden CA, and Henson PM. Recognition ligands on apoptotic cells: A perspective. J Leukoc Biol 79: 896-903, 2006.
48. Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T, Rubio N, Firczuk M, Mathieu C, Roebroek AJ, Annaert W, Golab J, De Witte P, Vandenabeele P, and Agostinis P. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J 31: 1062-1079, 2012.
49. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, Perfettini JL, Schlemmer F, Tasdemir E, UhlM, Genin P, Civas A, Ryffel B, Kanellopoulos J, Tschopp J, Andre F, Lidereau R, McLaughlin NM, Haynes NM, Smyth MJ, Kroemer G, and Zitvogel L. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15: 1170-1178, 2009.
50. Green DR, Ferguson T, Zitvogel L, and Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol 9: 353-363, 2009.
51. Grivennikov SI, Greten FR, and Karin M. Immunity, inflammation, and cancer. Cell 140: 883-899, 2010.
52. Halama N, Michel S, Kloor M, Zoernig I, Benner A, Spille A, Pommerencke T, von Knebel DM, Folprecht G, Luber B, Feyen N, Martens UM, Beckhove P, Gnjatic S, Schirmacher P, Herpel E, Weitz J, Grabe N, and Jaeger D. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res 71: 5670-5677, 2011.
53. Hao Q, Du XQ, Fu X, and Tian J. [Expression and clinical significance of HMGB1 and RAGE in cervical squamous cell carcinoma]. Zhonghua Zhong Liu Za Zhi 30: 292-295, 2008.
54. Hausler SF, Montalban Del Barrio I, Strohschein J, Anoop Chandran P, Engel JB, Honig A, Ossadnik M, Horn E, Fischer B, Krockenberger M, Heuer S, Seida AA, Junker M, Kneitz H, Kloor D, Klotz KN, Dietl J, and Wischhusen J. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity. Cancer Immunol Immunother 60: 1405-1418, 2011.
55. Huttunen HJ, Fages C, Kuja-Panula J, Ridley AJ, and Rauvala H. Receptor for advanced glycation end productsbinding COOH-Terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res 62: 4805-4811, 2002.
56. Idzko M, Dichmann S, Ferrari D, Di Virgilio F, la Sala A, Girolomoni G, Panther E, and Norgauer J. Nucleotides induce chemotaxis and actin polymerization in immature but not mature human dendritic cells via activation of pertussis toxin-sensitive P2y receptors. Blood 100: 925-932, 2002.
57. Ishiguro H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y, and Uemura H. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 64: 92-100, 2005.
58. Iyer SS, Pulskens WP, Sadler JJ, Butter LM, Teske GJ, Ulland TK, Eisenbarth SC, Florquin S, Flavell RA, Leemans JC, and Sutterwala FS. Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc Natl Acad Sci U S A 106: 20388-20393, 2009.
59. Jacob K, Wach F, Holzapfel U, Hein R, Lengyel E, Buettner R, and Bosserhoff AK. In vitro modulation of human melanoma cell invasion and proliferation by all-Trans-retinoic acid. Melanoma Res 8: 211-219, 1998.
60. Kanneganti TD, Body-Malapel M, Amer A, Park JH, Whitfield J, Franchi L, Taraporewala ZF, Miller D, Patton JT, Inohara N, and Nunez G. Critical role for Cryopyrin/ Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA. J Biol Chem 281: 36560-36568, 2006.
61. Kanneganti TD, Lamkanfi M, and Nunez G. Intracellular NOD-like receptors in host defense and disease. Immunity 27: 549-559, 2007.
62. Kobayashi H, Wood M, Song Y, Appella E, and Celis E. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Res 60: 5228-5236, 2000.
63. Kondo T, Nakazawa T, Murata SI, and Katoh R. Expression of CD73 and its ecto-5'-nucleotidase activity are elevated in papillary thyroid carcinomas. Histopathology 48: 612-614, 2006.
64. Kono H and Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol 8: 279-289, 2008.
65. Krause KH and Michalak M. Calreticulin. Cell 88: 439-443, 1997.
66. Krelin Y, Voronov E, Dotan S, Elkabets M, Reich E, Fogel M, Huszar M, Iwakura Y, Segal S, Dinarello CA, and Apte RN. Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogeninduced tumors. Cancer Res 67: 1062-1071, 2007.
67. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, Blagosklonny MV, El-Deiry WS, Golstein P, Green DR, Hengartner M, Knight RA, Kumar S, Lipton SA, Malorni W, Nunez G, Peter ME, Tschopp J, Yuan J, Piacentini M, Zhivotovsky B, and Melino G. Classification of cell death: Recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 16: 3-11, 2009.
68. Kroemer G and Zitvogel L. Can the exome and the immunome converge on the design of efficient cancer vaccines?. Oncoimmunology 1: 579-580, 2012.
69. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, and Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 12: 860-875, 2012.
70. Krysko DV and Vandenabeele P. From regulation of dying cell engulfment to development of anti-cancer therapy. Cell Death Differ 15: 29-38, 2008.
71. Kuniyasu H, Chihara Y, Kondo H, Ohmori H, and Ukai R. Amphoterin induction in prostatic stromal cells by androgen deprivation is associated with metastatic prostate cancer. Oncol Rep 10: 1863-1868, 2003.
72. Kuniyasu H, Oue N, Wakikawa A, Shigeishi H, Matsutani N, Kuraoka K, Ito R, Yokozaki H, and Yasui W. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 196: 163-170, 2002.
73. Kunzli BM, Bernlochner MI, Rath S, Kaser S, Csizmadia E, Enjyoji K, Cowan P, d'Apice A, Dwyer K, Rosenberg R, Perren A, Friess H, Maurer CA, and Robson SC. Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer. Purinergic Signal 7: 231-241, 2011.
74. Ladoire S, Mignot G, Dabakuyo S, Arnould L, Apetoh L, Rebe C, Coudert B, Martin F, Bizollon MH, Vanoli A, Coutant C, Fumoleau P, Bonnetain F, and Ghiringhelli F. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol 224: 389-400, 2011.
75. Leth-Larsen R, Lund R, Hansen HV, Laenkholm AV, Tarin D, Jensen ON, and Ditzel HJ. Metastasis-related plasma membrane proteins of human breast cancer cells identified by comparative quantitative mass spectrometry. Mol Cell Proteomics 8: 1436-1449, 2009.
76. Livesey KM, Kang R, Vernon P, Buchser W, Loughran P, Watkins SC, Zhang L, Manfredi JJ, Zeh HJ, 3rd, Li L, Lotze MT, and Tang D. p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Res 72: 1996-2005, 2012.
77. Lotze MT and Tracey KJ. High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol 5: 331-342, 2005.
78. Ludwig HC, Rausch S, Schallock K, and Markakis E. Expression of CD 73 (ecto-5'-nucleotidase) in 165 glioblastomas by immunohistochemistry and electronmicroscopic histochemistry. Anticancer Res 19: 1747-1752, 1999.
79. Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Witzig TE, Kumar S, Hayman SR, Russell SJ, Buadi FK, Geyer SM, Campbell ME, Kyle RA, Rajkumar SV, Greipp PR, Kline MP, Xiong Y, Moon-Tasson LL, and Donovan KA. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc 84: 114-122, 2009.
80. Ma Y, Aymeric L, Locher C, Mattarollo SR, Delahaye NF, Pereira P, Boucontet L, Apetoh L, Ghiringhelli F, Casares N, Lasarte JJ, Matsuzaki G, Ikuta K, Ryffel B, Benlagha K, Tesniere A, Ibrahim N, Dechanet-Merville J, Chaput N, Smyth MJ, Kroemer G, and Zitvogel L. Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med 208: 491-503, 2011.
81. Manfredi AA, Capobianco A, Esposito A, De Cobelli F, Canu T, Monno A, Raucci A, Sanvito F, Doglioni C, Nawroth PP, Bierhaus A, Bianchi ME, Rovere-Querini P, and Del Maschio A. Maturing dendritic cells depend on RAGE for in vivo homing to lymph nodes. J Immunol 180: 2270-2275, 2008.
82. Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, Roose-Girma M, Lee WP, Weinrauch Y, Monack DM, and Dixit VM. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440: 228-232, 2006.
83. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 6: 823-835, 2006.
84. Martinon F, Chen X, Lee AH, and Glimcher LH. TLR activation of the transcription factor XBP1 regulates innate immune responses in macrophages. Nat Immunol 11: 411-418, 2010.
85. Martinon F, Mayor A, and Tschopp J. The inflammasomes: Guardians of the body. Annu Rev Immunol.27: 229-265, 2009.
86. Martins I, Kepp O, Schlemmer F, Adjemian S, Tailler M, Shen S, Michaud M, Menger L, Gdoura A, Tajeddine N, Tesniere A, Zitvogel L, and Kroemer G. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 30: 1147-1158, 2011.
87. Martins I, Tesniere A, Kepp O, Michaud M, Schlemmer F, Senovilla L, Seror C, Metivier D, Perfettini JL, Zitvogel L, and Kroemer G. Chemotherapy induces ATP release from tumor cells. Cell Cycle 8: 3723-3728, 2009.
88. Mattarollo SR, Loi S, Duret H, Ma Y, Zitvogel L, and Smyth MJ. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res 71: 4809-4820, 2011.
89. Matzinger P. The danger model: A renewed sense of self. Science 296: 301-305, 2002.
90. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 12: 991-1045, 1994.
91. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 1: 135-145, 2001.
92. Melvin VS, Harrell C, Adelman JS, Kraus WL, Churchill M, and Edwards DP. The role of the C-Terminal extension (CTE) of the estrogen receptor alpha and beta DNA binding domain in DNA binding and interaction with HMGB. J Biol Chem 279: 14763-14771, 2004.
93. Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Shen S, Yamazaki T, Sukkurwala AQ, Michaud M, Mignot G, Schlemmer F, Sulpice E, Locher C, Gidrol X, Ghiringhelli F, Modjtahedi N, Galluzzi L, Andre F, Zitvogel L, Kepp O, and Kroemer G. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med 4: 143ra99, 2012.
94. Messmer D, Yang H, Telusma G, Knoll F, Li J, Messmer B, Tracey KJ, and Chiorazzi N. High mobility group box protein 1: An endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 173: 307-313, 2004.
95. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S, Kepp O, Scoazec M, Mignot G, Rello-Varona S, Tailler M, Menger L, Vacchelli E, Galluzzi L, Ghiringhelli F, di Virgilio F, Zitvogel L, and Kroemer G. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334: 1573-1577, 2011.
96. Mitola S, Belleri M, Urbinati C, Coltrini D, Sparatore B, Pedrazzi M, Melloni E, and Presta M. Cutting edge: Extracellular high mobility group box-1 protein is a proangiogenic cytokine. J Immunol 176: 12-15, 2006.
97. Moser B, Desai DD, Downie MP, Chen Y, Yan SF, Herold K, Schmidt AM, and Clynes R. Receptor for advanced glycation end products expression on T cells contributes to antigen-specific cellular expansion in vivo. J Immunol 179: 8051-8058, 2007.
98. Muller S, Scaffidi P, Degryse B, Bonaldi T, Ronfani L, Agresti A, Beltrame M, and Bianchi ME. New EMBO members' review: The double life of HMGB1 chromatin protein: Architectural factor and extracellular signal. EMBO J 20: 4337-4340, 2001.
99. Nakao S, Kuwano T, Tsutsumi-Miyahara C, Ueda S, Kimura YN, Hamano S, Sonoda KH, Saijo Y, Nukiwa T, Strieter RM, Ishibashi T, Kuwano M, and Ono M. Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth. J Clin Invest 115: 2979-2991, 2005.
100. Nestl A, Von Stein OD, Zatloukal K, Thies WG, Herrlich P, Hofmann M, and Sleeman JP. Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. Cancer Res 61: 1569-1577, 2001.
101. Obeid M, Panaretakis T, Joza N, Tufi R, Tesniere A, van Endert P, Zitvogel L, and Kroemer G. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ 14: 1848-1850, 2007.
102. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Metivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, and Kroemer G. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13: 54-61, 2007.
103. Ogura Y, Sutterwala FS, and Flavell RA. The inflammasome: First line of the immune response to cell stress. Cell 126: 659-662, 2006.
104. Oh HK, Sin JI, Choi J, Park SH, Lee TS, and Choi YS. Overexpression of CD73 in epithelial ovarian carcinoma is associated with better prognosis, lower stage, better differentiation and lower regulatory T cell infiltration. J Gynecol Oncol 23: 274-281, 2012.
105. Okamoto M, Liu W, Luo Y, Tanaka A, Cai X, Norris DA, Dinarello CA, and Fujita M. Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta. J Biol Chem 285: 6477-6488, 2010.
106. Oppenheim JJ and Yang D. Alarmins: Chemotactic activators of immune responses. Curr Opin Immunol 17: 359-365, 2005.
107. Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, and Fridman WH. Immune infiltration in human tumors: A prognostic factor that should not be ignored. Oncogene 29: 1093-1102, 2010.
108. Palumbo R, Galvez BG, Pusterla T, De Marchis F, Cossu G, Marcu KB, and Bianchi ME. Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kappaB activation. J Cell Biol 179: 33-40, 2007.
109. Panaretakis T, Joza N, Modjtahedi N, Tesniere A, Vitale I, Durchschlag M, Fimia GM, Kepp O, Piacentini M, Froehlich KU, van Endert P, Zitvogel L, Madeo F, and Kroemer G. The co-Translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ 15: 1499-1509, 2008.
110. Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC, Durchschlag M, Joza N, Pierron G, van Endert P, Yuan J, Zitvogel L, Madeo F, Williams DB, and Kroemer G. Mechanisms of pre-Apoptotic calreticulin exposure in immunogenic cell death. EMBO J 28: 578-590, 2009.
111. Park JS, Arcaroli J, Yum HK, Yang H, Wang H, Yang KY, Choe KH, Strassheim D, Pitts TM, Tracey KJ, and Abraham E. Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Physiol Cell Physiol 284: C870-C879, 2003.
112. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D, Sohn JW, Yamada S, Maruyama I, Banerjee A, Ishizaka A, and Abraham E. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 290: C917-C924, 2006.
113. Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, Sattar H, Wang Y, Brown NK, Greene M, Liu Y, Tang J, Wang S, and Fu YX. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 18: 160-170, 2010.
114. Parkkinen J, Raulo E, Merenmies J, Nolo R, Kajander EO, Baumann M, and Rauvala H. Amphoterin, the 30-kDa protein in a family of HMG1-Type polypeptides. Enhanced expression in transformed cells, leading edge localization, and interactions with plasminogen activation. J Biol Chem 268: 19726-19738, 1993.
115. Parkkinen J and Rauvala H. Interactions of plasminogen and tissue plasminogen activator (t-PA) with amphoterin. Enhancement of t-PA-catalyzed plasminogen activation by amphoterin. J Biol Chem 266: 16730-16735, 1991.
116. Poser I and Bosserhoff AK. Transcription factors involved in development and progression of malignant melanoma. Histol Histopathol 19: 173-188, 2004.
117. Poser I, Golob M, Buettner R, and Bosserhoff AK. Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol 23: 2991-2998, 2003.
118. Pulte D, Furman RR, Broekman MJ, Drosopoulos JH, Ballard HS, Olson KE, Kizer JR, and Marcus AJ. CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 11: 367-372, 2011.
119. Qin Y, Ekmekcioglu S, Liu P, Duncan LM, Lizee G, Poindexter N, and Grimm EA. Constitutive aberrant endogenous interleukin-1 facilitates inflammation and growth in human melanoma. Mol Cancer Res 9: 1537-1550, 2011.
120. Rao RV, Ellerby HM, and Bredesen DE. Coupling endoplasmic reticulum stress to the cell death program. Cell Death Differ 11: 372-380, 2004.
121. Rauvala H, Huttunen HJ, Fages C, Kaksonen M, Kinnunen T, Imai S, Raulo E, and Kilpelainen I. Heparin-binding proteins HB-GAM (pleiotrophin) and amphoterin in the regulation of cell motility. Matrix Biol 19: 377-387, 2000.
122. Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, Tredan O, Verweij J, Biron P, Labidi I, Guastalla JP, Bachelot T, Perol D, Chabaud S, Hogendoorn PC, Cassier P, Dufresne A, and Blay JY. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 69: 5383-5391, 2009.
123. Reed JR, Leon RP, Hall MK, and Schwertfeger KL. Interleukin-1beta and fibroblast growth factor receptor 1 cooperate to induce cyclooxygenase-2 during early mammary tumourigenesis. Breast Cancer Res 11: R21, 2009.
124. Ronchetti A, Rovere P, Iezzi G, Galati G, Heltai S, Protti MP, Garancini MP, Manfredi AA, Rugarli C, and Bellone M. Immunogenicity of apoptotic cells in vivo: Role of antigen load, antigen-presenting cells, and cytokines. J Immunol 163: 130-136, 1999.
125. Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B, Catalanotti F, Giazzon M, Dumitriu IE, Muller S, Iannacone M, Traversari C, Bianchi ME, and Manfredi AA. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 5: 825-830, 2004.
126. Rovere P, Vallinoto C, Bondanza A, Crosti MC, Rescigno M, Ricciardi-Castagnoli P, Rugarli C, and Manfredi AA. Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J Immunol 161: 4467-4471, 1998.
127. Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, and Coussens LM. Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A 109: 2796-2801, 2012.
128. Sancho D, Joffre OP, Keller AM, Rogers NC, Martinez D, Hernanz-Falcon P, Rosewell I, and Reis e Sousa C. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature 458: 899-903, 2009.
129. Sancho D, Mourao-Sa D, Joffre OP, Schulz O, Rogers NC, Pennington DJ, Carlyle JR, and Reis e Sousa C. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-Type lectin. J Clin Invest 118: 2098-2110, 2008.
130. Sasahira T, Akama Y, Fujii K, and Kuniyasu H. Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas. Virchows Arch 446: 411-415, 2005.
131. Savill J and Fadok V. Corpse clearance defines the meaning of cell death. Nature 407: 784-788, 2000.
132. Scaffidi P, Misteli T, and Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191-195, 2002.
133. Schafer M and Werner S. Cancer as an overhealing wound: An old hypothesis revisited. Nat Rev Mol Cell Biol 9: 628-638, 2008.
134. Schauer IG, Sood AK, Mok S, and Liu J. Cancer-Associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia 13: 393-405, 2011.
135. Scherbarth S and Orr FW. Intravital videomicroscopic evidence for regulation of metastasis by the hepatic microvasculature: Effects of interleukin-1alpha on metastasis and the location of B16F1 melanoma cell arrest. Cancer Res 57: 4105-4110, 1997.
136. Schlueter C, Weber H, Meyer B, Rogalla P, Roser K, Hauke S, and Bullerdiek J. Angiogenetic signaling through hypoxia: HMGB1: An angiogenetic switch molecule. Am J Pathol 166: 1259-1263, 2005.
137. Schonthal AH. Pharmacological targeting of endoplasmic reticulum stress signaling in cancer. Biochem Pharmacol 85: 653-666, 2013.
138. Schroder K and Tschopp J. The inflammasomes. Cell 140: 821-832, 2010.
139. Semino C, Angelini G, Poggi A, and Rubartelli A. NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood 106: 609-616, 2005.
140. Serra S, Horenstein AL, Vaisitti T, Brusa D, Rossi D, Laurenti L, D'Arena G, Coscia M, Tripodo C, Inghirami G, Robson SC, Gaidano G, Malavasi F, and Deaglio S. CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood 118: 6141-6152, 2011.
141. Shiratsuchi A, Watanabe I, Takeuchi O, Akira S, and Nakanishi Y. Inhibitory effect of Toll-like receptor 4 on fusion between phagosomes and
142. Stagg J, Divisekera U, Duret H, Sparwasser T, Teng MW, Darcy PK, and Smyth MJ. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res 71: 2892-2900, 2011.
143. Stros M, Ozaki T, Bacikova A, Kageyama H, and Nakagawara A. HMGB1 and HMGB2 cell-specifically downregulate the p53-And p73-dependent sequence-specific transactivation from the human Bax gene promoter. J Biol Chem 277: 7157-7164, 2002.
144. Takada M, Hirata K, Ajiki T, Suzuki Y, and Kuroda Y. Expression of receptor for advanced glycation end products (RAGE) and MMP-9 in human pancreatic cancer cells. Hepatogastroenterology 51: 928-930, 2004.
145. Takeda K, Kaisho T, and Akira S. Toll-like receptors. Annu Rev Immunol 21: 335-376, 2003.
146. Terme M, Ullrich E, Aymeric L, Meinhardt K, Desbois M, Delahaye N, Viaud S, Ryffel B, Yagita H, Kaplanski G, Prevost-Blondel A, Kato M, Schultze JL, Tartour E, Kroemer G, Chaput N, and Zitvogel L. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res 71: 5393-5399, 2011.
147. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, Aymeric L, Michaud M, Apetoh L, Barault L, Mendiboure J, Pignon JP, Jooste V, van Endert P, Ducreux M, Zitvogel L, Piard F, and Kroemer G. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29: 482-491, 2010.
148. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sirois C, Hua J, An LL, Audoly L, La Rosa G, Bierhaus A, Naworth P, Marshak-Rothstein A, Crow MK, Fitzgerald KA, Latz E, Kiener PA, and Coyle AJ. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 8: 487-496, 2007.
149. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, and Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454, 2012.
150. Tu S, Bhagat G, Cui G, Takaishi S, Kurt-Jones EA, Rickman B, Betz KS, Penz-Oesterreicher M, Bjorkdahl O, Fox JG, and Wang TC. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 14: 408-419, 2008.
151. Ullrich E, Bonmort M, Mignot G, Kroemer G, and Zitvogel L. Tumor stress, cell death and the ensuing immune response. Cell Death Differ 15: 21-28, 2008.
152. van Deventer HW, Burgents JE, Wu QP, Woodford RM, Brickey WJ, Allen IC, McElvania-Tekippe E, Serody JS, and Ting JP. The inflammasome component NLRP3 impairs antitumor vaccine by enhancing the accumulation of tumor-Associated myeloid-derived suppressor cells. Cancer Res 70: 10161-10169, 2011.
153. Veerman AJ, Hogeman PH, van Zantwijk CH, and Bezemer PD. Prognostic value of 5¢ nucleotidase in acute lymphoblastic leukemia with the common-ALL phenotype. Leuk Res 9: 1227-1229, 1985.
154. Venereau E, Casalgrandi M, Schiraldi M, Antoine DJ, Cattaneo A, De Marchis F, Liu J, Antonelli A, Preti A, Raeli L, Shams SS, Yang H, Varani L, Andersson U, Tracey KJ, Bachi A, Uguccioni M, and Bianchi ME. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med 209: 1519-1528, 2012.
155. Venneri MA, De Palma M, Ponzoni M, Pucci F, Scielzo C, Zonari E, Mazzieri R, Doglioni C, and Naldini L. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 109: 5276-5285, 2007.
156. Vidal-Vanaclocha F, Fantuzzi G, Mendoza L, Fuentes AM, Anasagasti MJ, Martin J, Carrascal T, Walsh P, Reznikov LL, Kim SH, Novick D, Rubinstein M, and Dinarello CA. IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Natl Acad Sci U S A 97: 734-739, 2000.
157. Volp K, Brezniceanu ML, Bosser S, Brabletz T, Kirchner T, Gottel D, Joos S, and Zornig M. Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut 55: 234-242, 2006.
158. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, and Tracey KJ. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248-251, 1999.
159. Wang S, Astsaturov IA, Bingham CA, McCarthy KM, von Mehren M, Xu W, Alpaugh RK, Tang Y, Littlefield BA, Hawkins LD, Ishizaka ST, and Weiner LM. Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment. Cancer Immunol Immunother 61: 49-61, 2012.
160. Weinreich DM, Elaraj DM, Puhlmann M, Hewitt SM, Carroll NM, Feldman ED, Turner EM, Spiess PJ, and Alexander HR. Effect of interleukin 1 receptor antagonist gene transduction on human melanoma xenografts in nude mice. Cancer Res 63: 5957-5961, 2003.
161. West NR, Milne K, Truong PT, Macpherson N, Nelson BH, and Watson PH. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res 13: R126, 2011.
162. Wieten E, van Der Linden-Schrever BE, Sonneveld E, Veerman AJ, and Pieters R. CD73 (5'-nucleotidase) expression has no prognostic value in children with acute lymphoblastic leukemia. Leukemia 25: 1374-1376, 2011.
163. Wu XR, He XS, Chen YF, Yuan RX, Zeng Y, Lian L, Zou YF, Lan N, Wu XJ, and Lan P. High expression of CD73 as a poor prognostic biomarker in human colorectal cancer. J Surg Oncol 106: 130-137, 2012.
164. Yousif NG and Al-Amran FG. Novel Toll-like receptor-4 deficiency attenuates trastuzumab (Herceptin) induced cardiac injury in mice. BMC Cardiovasc Disord 11: 62, 2011.
165. Yu W, Kim J, and Ossowski L. Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J Cell Biol 137: 767-777, 1997.
166. Zappasodi R, Pupa SM, Ghedini GC, Bongarzone I, Magni M, Cabras AD, Colombo MP, Carlo-Stella C, Gianni AM, and Di Nicola M. Improved clinical outcome in indolent Bcell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. Cancer Res 70: 9062-9072, 2010.
167. Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, and Kroemer G. The anticancer immune response: Indispensable for therapeutic success?. J Clin Invest 118: 1991-2001, 2008.
168. Zitvogel L, Apetoh L, Ghiringhelli F, and Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8: 59-73, 2008.
169. Zitvogel L, Kepp O, Galluzzi L, and Kroemer G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol 13: 343-351, 2012.
170. Zitvogel L, Kepp O, and Kroemer G. Decoding cell death signals in inflammation and immunity. Cell 140: 798-804, 2010.
171. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6: 295-307, 2006.